0000000000825116

AUTHOR

Maria Lina Mezzatesta

0000-0003-0853-9564

showing 2 related works from this author

Extended-spectrum beta-lactamase-producing and carbapenemase-producing Enterobacter cloacae ventriculitis successfully treated with intraventricular …

2014

SummaryWe present a case of post-neurosurgical ventriculitis caused by carbapenemase-producing Enterobacter cloacae successfully treated with intraventricular colistin. Enterobacter spp are intrinsically resistant to aminopenicillins, cefazolin, and cefoxitin due to the production of constitutive chromosomal AmpC beta-lactamases. Moreover, extended-spectrum beta-lactamase-producing Enterobacter spp have been identified in the USA and Europe, and carbapenems are considered the drug of choice in these cases. Our isolate was sensitive only to fosfomycin, tigecycline, and colistin, and 6 days of intravenous colistin had failed to eradicate the infection. This case provides clinical evidence to …

MaleMicrobiology (medical)Intraventricularmedicine.medical_treatmentTigecyclineFosfomycinCeftazidimebeta-LactamasesCerebral VentriculitisMicrobiologyBacterial ProteinsEnterobacteriaceaeDrug Resistance Multiple BacterialEnterobacter cloacaeVentriculitispolycyclic compoundsVentriculitismedicineHumansMeningitisCefoxitinCarbapenemases Colistin Enterobacter cloacaeAmikacinbiologyColistinbusiness.industryEnterobacteriaceae InfectionsGeneral MedicineEnterobacterbiochemical phenomena metabolism and nutritionCarbapenemasesbacterial infections and mycosesmedicine.diseasebiology.organism_classificationAnti-Bacterial AgentsTreatment OutcomeInfectious DiseasesChild PreschoolBeta-lactamaseColistinbacteriaAdministration Intravenouslipids (amino acids peptides and proteins)TeicoplaninbusinessEnterobacter cloacaemedicine.drugInternational Journal of Infectious Diseases
researchProduct

Combination of aztreonam, ceftazidime–avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis

2021

Abstract We describe a challenging case of patient with metallo-beta-lactamase-producing Pseudomonas aeruginosa sternal osteomyelitis following aortic valve replacement with biological prosthesis. The strain exhibited a multidrug-resistance phenotype carrying the blaVIM-1 gene and belonged to the high-risk clone sequence type ST235. The patient was successfully treated with surgical debridement plus antibiotic therapy with ceftazidime/avibactam, aztreonam, and amikacin. Time-kill curves showed that this triple antibiotic combination at 1 × MIC was strongly synergic after 8 h, achieving 99.9% killing and maintaining this until 48 h.

Microbiology (medical)AvibactamDrug ResistanceCeftazidimeInfectious and parasitic diseasesRC109-216Aztreonammedicine.disease_causeST235CeftazidimeMicrobiologyCeftazidime–avibactamchemistry.chemical_compoundAztreonamAortic valve replacementDrug TherapyDrug Resistance Multiple BacterialmedicineHumansPseudomonas InfectionsPseudomonas aeruginosa; ST235; VIM-1; aztreonam; ceftazidime-avibactam; osteomyelitisAmikacinAgedPseudomonas aeruginosabusiness.industryceftazidime-avibactamOsteomyelitisBacterialOsteomyelitisGeneral MedicineCeftazidime/avibactammedicine.diseaseAnti-Bacterial AgentsDrug CombinationsInfectious DiseaseschemistryDebridementAmikacinPseudomonas aeruginosaCombinationVIM-1Drug Therapy CombinationFemalebusinessAzabicyclo CompoundsMultiplemedicine.drug
researchProduct